JP2007535551A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007535551A5 JP2007535551A5 JP2007510964A JP2007510964A JP2007535551A5 JP 2007535551 A5 JP2007535551 A5 JP 2007535551A5 JP 2007510964 A JP2007510964 A JP 2007510964A JP 2007510964 A JP2007510964 A JP 2007510964A JP 2007535551 A5 JP2007535551 A5 JP 2007535551A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- phenyl
- optionally substituted
- hydrogen
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001931 aliphatic group Chemical group 0.000 claims 31
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 239000011593 sulfur Substances 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- -1 1,2-methylene Chemical group 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 150000001721 carbon Chemical class 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 241000790917 Dioxys <bee> Species 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000000284 extract Substances 0.000 claims 1
- 210000003608 fece Anatomy 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 239000011435 rock Substances 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000000582 semen Anatomy 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56587904P | 2004-04-28 | 2004-04-28 | |
| PCT/US2005/014558 WO2005105780A2 (en) | 2004-04-28 | 2005-04-27 | Compositions useful as inhibitors of rock and other protein kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007535551A JP2007535551A (ja) | 2007-12-06 |
| JP2007535551A5 true JP2007535551A5 (https=) | 2008-06-19 |
Family
ID=34979422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007510964A Pending JP2007535551A (ja) | 2004-04-28 | 2005-04-27 | Ｒｏｃｋおよび他のプロテインキナーゼの阻害剤として有用な組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7531556B2 (https=) |
| EP (1) | EP1751133B1 (https=) |
| JP (1) | JP2007535551A (https=) |
| AT (1) | ATE464303T1 (https=) |
| DE (1) | DE602005020611D1 (https=) |
| WO (1) | WO2005105780A2 (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL169855A (en) * | 2005-07-25 | 2014-05-28 | Elta Systems Ltd | A system and method for locating a receiver location |
| AR058439A1 (es) | 2005-07-26 | 2008-02-06 | Portela & Ca Sa | Derivados de nitrocatecol como inhibidores de comt. procesos de obtencion y composiciones farmaceuticas. |
| US8211919B2 (en) | 2005-09-02 | 2012-07-03 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
| EP1845097A1 (en) * | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| US20090118336A1 (en) * | 2006-05-03 | 2009-05-07 | Laurent David | Pyrazole derivatives and their use as pi3k inhibitors |
| UA95641C2 (xx) * | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| EP2044061A2 (en) * | 2006-07-20 | 2009-04-08 | Mehmet Kahraman | Benzothiophene inhibitors of rho kinase |
| US8492378B2 (en) | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
| US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| EP2481410B1 (en) | 2007-01-31 | 2016-07-13 | BIAL - Portela & Ca., S.A. | Nitrocatechol derivates as COMT inhibitors administered with a specific dosage regime |
| JPWO2008093737A1 (ja) | 2007-01-31 | 2010-05-20 | 大日本住友製薬株式会社 | アミド誘導体 |
| WO2009108077A2 (en) * | 2008-02-28 | 2009-09-03 | Bial - Portela & Ca., S.A. | Pharmaceutical composition for poorly soluble drugs |
| KR20110002462A (ko) | 2008-03-17 | 2011-01-07 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 5-[3-(2,5-디클로로-4,6-디메틸-1-옥시-피리딘-3-일)-[1,2,4]옥사디아졸-5-일]-3-나이트로벤젠-1,2-디올의 결정형 |
| MX2010014234A (es) * | 2008-06-19 | 2011-03-25 | Astrazeneca Ab | Compuestos pirazol 436. |
| TWI461423B (zh) * | 2008-07-02 | 2014-11-21 | Astrazeneca Ab | 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物 |
| GB0812648D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
| DE102008038220A1 (de) * | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Oxadiazolderivate |
| AU2010231961B2 (en) * | 2009-04-01 | 2015-05-21 | Bial - Portela & Ca., S.A. | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
| RU2550133C2 (ru) * | 2009-04-01 | 2015-05-10 | БИАЛ-ПОРТЕЛА энд КА., С.А. | Фармацевтические составы, включающие производные нитрокатехола, и способы их получения |
| WO2012100223A1 (en) * | 2011-01-21 | 2012-07-26 | John Irwin | Synthetic lethal targeting of glucose transport |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| KR102021157B1 (ko) | 2011-04-01 | 2019-09-11 | 제넨테크, 인크. | Ａｋｔ 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법 |
| TR201815685T4 (tr) | 2011-04-01 | 2018-11-21 | Genentech Inc | Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları. |
| WO2013089573A1 (en) | 2011-12-13 | 2013-06-20 | BIAL - PORTELA & Cª., S.A. | Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor |
| US20140179712A1 (en) | 2012-12-21 | 2014-06-26 | Astrazeneca Ab | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide |
| CN105764501A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群治疗效益的组合物 |
| CN105849098A (zh) * | 2013-11-06 | 2016-08-10 | 百时美施贵宝公司 | Gsk-3抑制剂 |
| CN105849097A (zh) * | 2013-11-06 | 2016-08-10 | 百时美施贵宝公司 | 取代的吡啶衍生物用作gsk-3抑制剂 |
| JP2018500300A (ja) | 2014-11-28 | 2018-01-11 | ノヴィファーマ，エス．アー． | パーキンソン病を遅延させるための医薬 |
| EP4088719A1 (en) | 2015-10-13 | 2022-11-16 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
| WO2017064119A1 (en) | 2015-10-13 | 2017-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
| JP7114076B2 (ja) * | 2015-12-22 | 2022-08-08 | シャイ・セラピューティクス・エルエルシー | がん及び炎症性疾患の処置のための化合物 |
| JP7514005B2 (ja) | 2017-06-21 | 2024-07-10 | シャイ・セラピューティクス・エルエルシー | がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物 |
| JP7407461B2 (ja) | 2018-12-19 | 2024-01-04 | シャイ・セラピューティクス・エルエルシー | がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物 |
| CR20220375A (es) * | 2020-01-07 | 2022-09-22 | Disarm Therapeutics Inc | Inhibidores de sarm1 |
| EP4192828A1 (en) * | 2020-08-04 | 2023-06-14 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
| TW202334117A (zh) | 2020-08-24 | 2023-09-01 | 美商達薩瑪治療公司 | Ｓａｒｍ１之抑制劑 |
| CN116438171A (zh) | 2020-09-16 | 2023-07-14 | 努拉生物公司 | 作为sarm1抑制剂的取代的吡啶衍生物 |
| WO2022265993A1 (en) | 2021-06-14 | 2022-12-22 | Scorpion Therapeutics, Inc. | Urea derivatives which can be used to treat cancer |
| MX2024001322A (es) | 2021-07-28 | 2024-04-30 | Nura Bio Inc | Derivados de piridina sustituida como inhibidores de sarm1. |
| TW202320786A (zh) | 2021-08-10 | 2023-06-01 | 美商蕾瑞拉股份有限公司 | 用於毛髮治療的組合物、調配物及方法 |
| US12251459B2 (en) | 2022-10-12 | 2025-03-18 | Oddity Labs, Llc | Compositions, formulations, and methods for hair treatment |
| US20240208949A1 (en) * | 2022-12-05 | 2024-06-27 | Oddity Labs, Llc | Compositions, formulations, and methods for hair treatment |
| WO2025117429A1 (en) * | 2023-11-30 | 2025-06-05 | The Children's Medical Center Corporation | Methods and compositions for the treatment of blood cancer |
| WO2025224050A1 (en) | 2024-04-22 | 2025-10-30 | Institut National de la Santé et de la Recherche Médicale | Methods of treatment of patients suffering from hypomelanosis of ito |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| JPH0741485A (ja) | 1993-07-30 | 1995-02-10 | Katayama Seiyakushiyo:Kk | セフェム誘導体およびそれを含有する抗菌剤 |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| KR100581199B1 (ko) | 1998-06-19 | 2006-05-17 | 카이론 코포레이션 | 글리코겐 신타제 키나제 3의 억제제 |
| GB9828640D0 (en) | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
| US20020173507A1 (en) | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
| US20020111353A1 (en) * | 2000-12-05 | 2002-08-15 | Mark Ledeboer | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| AU2002308748A1 (en) | 2001-05-16 | 2002-11-25 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| EP1444009A1 (en) * | 2001-11-02 | 2004-08-11 | Pfizer Products Inc. | Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors |
| AU2003237121A1 (en) | 2002-04-26 | 2003-11-10 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| MXPA05001804A (es) * | 2002-08-14 | 2005-05-27 | Vertex Pharma | Inhibidores de proteinas cinasas y usos de los mismos. |
| EP1558607B1 (en) * | 2002-10-30 | 2010-05-05 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| WO2004083203A1 (en) | 2003-03-13 | 2004-09-30 | Vertex Pharmaceuticals Incorporated | Compositions useful as protein kinase inhibitors |
-
2005
- 2005-04-27 US US11/115,661 patent/US7531556B2/en not_active Expired - Fee Related
- 2005-04-27 WO PCT/US2005/014558 patent/WO2005105780A2/en not_active Ceased
- 2005-04-27 DE DE602005020611T patent/DE602005020611D1/de not_active Expired - Lifetime
- 2005-04-27 AT AT05744555T patent/ATE464303T1/de not_active IP Right Cessation
- 2005-04-27 EP EP05744555A patent/EP1751133B1/en not_active Expired - Lifetime
- 2005-04-27 JP JP2007510964A patent/JP2007535551A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007535551A5 (https=) | ||
| RU2328486C2 (ru) | Производные 2-пиридона в качестве ингибиторов нейтрофильной эластазы | |
| DE3781716T2 (de) | Mittel zur ortsspezifischen alkylierung. | |
| DE3340967C2 (de) | Aminderivate, Salze derselben, Verfahren zur Herstellung derselben sowie Anti-Ulcusmittel mit einem Gehalt derselben | |
| JP2005509024A5 (https=) | ||
| CA3206963A1 (en) | (hetero)aryl substituted sulfonyl-2-(1h-pyrrolo[2,3-b]pyridine-5-oxy) benzamide compounds and their use as apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| JP2017518959A5 (https=) | ||
| TW200604186A (en) | Compounds | |
| NO20062633L (no) | Pyrazolderivater som proteinkinasemodulatorer | |
| CA2324418A1 (en) | Novel opiate compounds, methods of making and methods of use | |
| JP2012530765A5 (https=) | ||
| JP2010520893A5 (https=) | ||
| RU2011127451A (ru) | ПРОИЗВОДНЫЕ ТИЕНО[3,2-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ РАКА | |
| JP2007505931A5 (https=) | ||
| JPWO2021000935A5 (https=) | ||
| RU2010113358A (ru) | Гуанидинсодержащие соединения, применимые в качестве антагонистов мускариновых рецепторов | |
| CA2617991A1 (en) | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | |
| JP2020519687A5 (https=) | ||
| JP2012524110A5 (https=) | ||
| JP2004536853A5 (https=) | ||
| JP2009514899A5 (https=) | ||
| CA2626402A1 (en) | Potassium channel inhibitors | |
| Okada et al. | Synthesis and antitumor activities of novel benzoylphenylurea derivatives | |
| AU2021328979A1 (en) | Pyrazole boronic acid compound, pharmaceutical composition containing same, and uses thereof | |
| JP2010513489A5 (https=) |